Option chain shows key data for Enveric Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Enveric Biosciences.

Enveric Biosciences (NASDAQ:ENVB) Stock, Option Chain

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Wall Street_Dow

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENVB

FLYW

GERN

MULN

PRCH

Dow Dips Over 100 Points; TJX Earnings Top Views

Nasdaq index

VERO

Nasdaq Surges 150 Points; Lowe&#39;s Posts Upbeat Earnings

What The Future Might Hold

Analyst Color

Asia

Earnings Beats

Earnings Misses

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Emerging Markets

Futures

Forex

Treasuries

Economics

Pre-Market Outlook

Analyst Ratings

ETFs

General

AXON

NVDA

SMCI

SONO

U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading.

US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&amp;P 500&#39;s Four-Day Fall Was A &#39;Non-Event,&#39; Says Expert

Enveric Biosciences Inc

Press Releases

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Clearmind Medicine

CNS Pharma

Evoke Pharma

Impact BioMedical

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

PainReform

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

XORTX Therapeutics

HC Wainwright & Co.

Doctor,Hand,Holding,A,Holographic,Of,Human,Brain,In,Healthcare

Biotech

Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Comments

Enveric Biosciences

Enveric Biosciences (ENVB) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell